Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
In a recent transaction filed with the Securities and Exchange Commission, Avantor, Inc. (NYSE:AVTR) Executive Vice President of Sales and Customer Excellence, Bramwell James, reported selling shares of the company’s common stock. The sales occurred over two days, February 26 and February 27, 2025, as the stock trades near its 52-week low of $16.46, having declined over 21% year-to-date.
On February 26, James sold 3,758 shares at a weighted average price of $17.53, with the transactions ranging from $17.47 to $17.60. The following day, he sold an additional 774 shares at a weighted average price of $17, with transactions ranging from $17.00 to $17.07. According to InvestingPro analysis, the stock currently appears slightly undervalued based on its Fair Value metrics.
The total value of these transactions amounted to $79,035. After these sales, James holds 86,605 shares of Avantor common stock. These transactions were conducted under a pre-established trading plan. For deeper insights into insider trading patterns and comprehensive analysis, including 8 additional ProTips, check out Avantor’s detailed InvestingPro Research Report.
In other recent news, Avantor Inc . reported its fourth-quarter 2024 earnings, revealing a mixed performance. The company exceeded earnings expectations with an adjusted earnings per share of $0.27, surpassing the analyst estimate of $0.26. However, revenue fell short, coming in at $1.69 billion compared to the consensus estimate of $1.71 billion, marking a 2% year-over-year decline. Despite these challenges, Avantor’s bioprocessing platform showed high-single-digit growth, with expectations for continued strength.
Analysts have adjusted their price targets for Avantor following these results. RBC Capital Markets reduced its price target from $33 to $31, maintaining an Outperform rating, while Bernstein lowered its target to $22 from $24.50, keeping a Market Perform rating. Stifel also revised its target to $26 from $28 but retained a Buy rating. These revisions reflect concerns about the company’s Laboratory Solutions segment and ambitious EBITDA goals for 2025.
Despite the price target cuts, analysts noted Avantor’s strong operational expense control and impressive free cash flow conversion of 110%. The company is actively using its cash flow to reduce debt, nearing its target leverage ratio of 3 times. Overall, Avantor’s strategic position and market fundamentals continue to be viewed positively by some analysts, even as the company navigates current challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.